Viewing nowDanjijanujeong 100 Milligrams (Sitagliptin Hydrochloride Hydrate)
Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Myeongmoon Pharmaceutical Co., Ltd.

MFDS item code 202004045 · Approved 2020.05.29 · Insurance code 649807940
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used in conjunction with dietary management and exercise therapy to assist in the control of blood sugar levels in patients with type 2 diabetes. It can be administered alone in patients who are starting treatment, and if monotherapy is insufficient, it can be taken in combination with metformin. Additionally, when blood sugar control is difficult with sulfonylureas, metformin, thiazolidinediones, or insulin monotherapy, this medication is added. It is used at various treatment stages and effectively improves blood sugar control in patients with type 2 diabetes.
Administer 100 mg once daily as monotherapy or combination therapy; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When this medicine is administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Assessment of renal function before starting treatment with this medicine and periodically thereafter is recommended, as dosage adjustment is required according to renal function. 1. No dosage adjustment is required in patients with mild renal impairment (eGFR ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is required in patients with moderate renal impairment (eGFR ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (eGFR ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (eGFR ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (eGFR < 15 mL/min/1.73 m2). This medicine may be administered without regard to the timing of dialysis.
This medication may cause severe allergic reactions; if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur after taking it, stop taking the medication immediately and seek medical attention. Additionally, serious inflammation of the pancreas, known as acute pancreatitis, may occur; therefore, if severe abdominal pain, vomiting, or nausea appears during use, consult a healthcare professional immediately. Patients with type 1 diabetes or diabetic ketoacidosis, as well as those who have had allergic reactions to this medication or its components, should not take it. Patients with impaired kidney function may have difficulties in excreting the drug, necessitating dose adjustment and regular kidney function tests. While taking this medication, there is a risk of hypoglycemia, especially when taken in conjunction with other hypoglycemic agents such as insulin or sulfonylureas; thus, blood sugar levels should be carefully monitored. Rare side effects such as severe joint pain or a blistering disease resembling dermatitis herpetiformis have been reported, and if these symptoms occur, consult a doctor immediately. The use of this medication is not recommended in pregnant or breastfeeding women, and safety and effectiveness have not been established for children or adolescents under 18 years of age. Elderly patients may experience decreased kidney function, so careful dose adjustments are needed, along with regular assessments of kidney function. In cases of overdose, general emergency measures should be followed, and if necessary, some of the drug can be removed through hemodialysis. This medication has minimal interactions with other drugs, but be sure to inform healthcare providers of any medication taken and receive appropriate monitoring.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is best stored at room temperature between 1°C and 30°C, avoiding extremely hot or cold environments.
Light orange, round, biconvex, film-coated tablet
30 tablets/box [10 tablets/PTPX3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowSitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Myeongmoon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Korea United Pharm., Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.